Trial Profile
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary) ; Peginterferon alfa-2a (Primary) ; Ritonavir (Primary)
- Indications Hepatitis D
- Focus Registrational; Therapeutic Use
- Acronyms D-LIVR
- Sponsors Eiger BioPharmaceuticals, Inc.
- 14 Nov 2023 Results presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 24 Jun 2023 48 week results evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta, presented at the European Association for the Study of the Liver Congress 2023
- 14 Jun 2023 This trial has been Completed in Sweden, According to European Clinical Trials Database record.